The current stock price of AXGN is 34.59 USD. In the past month the price increased by 5.46%. In the past year, price increased by 89.95%.
ChartMill assigns a technical rating of 10 / 10 to AXGN. When comparing the yearly performance of all stocks, AXGN is one of the better performing stocks in the market, outperforming 94.74% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to AXGN. AXGN has only an average score on both its financial health and profitability.
Over the last trailing twelve months AXGN reported a non-GAAP Earnings per Share(EPS) of 0.29. The EPS increased by 2089670227099910400% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.97% | ||
| ROE | -1.74% | ||
| Debt/Equity | 0.4 |
16 analysts have analysed AXGN and the average price target is 37.03 USD. This implies a price increase of 7.04% is expected in the next year compared to the current price of 34.59.
For the next year, analysts expect an EPS growth of 128.66% and a revenue growth 20.03% for AXGN
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
AXOGEN INC
13631 Progress Blvd., Suite 400
Alachua FLORIDA 32615 US
CEO: Karen Zaderej
Employees: 452
Phone: 13864626817
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 451 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
The current stock price of AXGN is 34.59 USD. The price decreased by -0.37% in the last trading session.
AXGN does not pay a dividend.
AXGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AXGN.
AXOGEN INC (AXGN) has a market capitalization of 1.60B USD. This makes AXGN a Small Cap stock.
The outstanding short interest for AXOGEN INC (AXGN) is 6.14% of its float.